Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11865177 | 0.85 | HPGD (0.42) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL3130427 | 0.82 | HIF1A (0.54) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL14429809 | 0.82 | HPGD (0.43) | HPGDKDM4EALDH1A1MAPTBCAT2 | |
| Dimethylamine SCHEMBL27639205 | 0.82 | MAPT (0.47) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL4422142 | 0.82 | NPC1 (0.46) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL28984805 | 0.81 | SETDB1 (0.49) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL4563077 | 0.81 | TAAR1 (0.50) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL7134588 | 0.81 | TSHR (0.54) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL19091144 | 0.81 | HPGD (0.45) | HPGDKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL8339183 | 0.81 | GAA (0.53) | HPGDKDM4EALDH1A1BCAT2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-2990401-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MASS SPECTROMETRY SIGNALS | Waters Technologies Corporation (US) | 2016-03-02 | — | — | EP | disclosed |
| CN-104418822-A | Compound with xanthine oxidase inhibition activity, and use thereof | NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD | 2015-03-18 | — | — | CN | disclosed |
| EP-2723745-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012178123-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2134341-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| WO-2008100448-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005090353-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | HPGD 3618/4885KDM4E 1641/4885ALDH1A1 4446/4885 |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | PDE3B, PDE3A, PDE4A | HPGD 386/4885KDM4E 411/4885ALDH1A1 2298/4885 |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HPGD 1004/4885KDM4E 1790/4885ALDH1A1 1869/4885 |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HPGD 1004/4885KDM4E 1790/4885ALDH1A1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.